Risk Factor Reduction

FDA Approved Medications

Alendronate sodium (Fosamax)

Calcitonin-salmon (Miacalcin)

Estrogen Therapy / Hormone Therapy

Ibandronate sodium (Boniva)

Risedronate sodium (Actonel)

Raloxifene hydrochloride (Evista)

Teriparatide (Forteo)

Zoledronic acid (Reclast)

Other Treatments

Raloxifene (Evista)

Prevention and treatment of osteoporosis should always include a nutrient-rich diet, the recommended intake of calcium and vitamin D, regular physical activity, safety precautions for fall prevention, avoidance of smoking and limited consumption of alcohol. If osteoporosis is diagnosed, you still must continue to make bone healthy lifestyle choices. However, lifestyle modifications alone are often not enough. Your healthcare provider may prescribe an osteoporosis medication to help stop further bone loss and reduce your risk for broken bones.

What are the medication options for osteoporosis?

The U.S. Food and Drug Administration (FDA) has approved several medications for osteoporosis which fall into two classes: antiresorptive medications and anabolic medications. Antiresorptive medications are used to strengthen bone, prevent bone loss and reduce the risk of fracture (broken bone).

The antiresorptive medications include a class of drugs called bisphosphonates.The four bisphosphonate medications are:

  • alendronate - available as a generic medication (Brand name: Fosamax, Fosamax D)
  • risedronate (Brand name: Actonel, Actonel with Calcium )
  • ibandronate ( Brand name: Boniva)
  • zoledronic acid (Brand name: Reclast)

Other approved antiresorptive medications include:

Anabolic medication builds new bone, increases bone density and helps reduce fracture risk. At this time the only approved anabolic medication is:

It is important to speak to your healthcare provider about the medication option that is right for you.


What is raloxifene (Evista)?

Raloxifene hydrochloride is the generic name for Evista (brand name). Raloxifene is in a class of medications known as selective estrogen receptor modulators, or SERMs. Raloxifene is not a hormone or an estrogen.

What is the use for raloxifene?

Raloxifene is FDA-approved for the prevention and treatment of osteoporosis in postmenopausal women.

How is raloxifene usually prescribed?

Raloxifene is prescribed as a 60 mg tablet taken once a day with or without food. When using Evista, it is recommended to get adequate calcium and vitamin D. It also important to follow the universal strategies for promotion of healthy bones.

What are the benefits of raloxifene?

Raloxifene improves bone mass throughout the skeleton and reduces the risk for spine fracture. Clinical studies are currently investigating the effect of raloxifene on hip and other non-spine fractures. Raloxifene may have potential effects on other parts of the body besides your bones; such as the heart, breast and uterus. The effect of raloxifene on the heart is unclear but a large trial is in progress that will give us more information. Studies thus far have indicated that raloxifene may have a protective effect on breast tissue.

What are the side effects of taking raloxifene?

Raloxifene may have potential adverse effects, such as an increase in hot flashes, an increased risk for blood clots in the leg veins or the lungs (similar to estrogen), leg cramps and fluid retention..

Like all medications, it is important to discuss all of the potential benefits and risks of taking this medication with your healthcare providerl. For more information about raloxifene (Evista) visit the Eli Lilly & Company website.






Home | About Us | Contact Us | In Your RegionSupport Groups
 In the News  | FAQSearch | Acknowledgements | Site Index
About Osteoporosis | Causes | ConsequencesPrevention
  Diagnosis | Treatment | WomenMen  | Children & Teens

The advice or information contained on these pages should NOT be construed as medical advice. Consult with your doctor or health care provider about your individual needs related to the prevention, diagnosis and treatment of osteoporosis.

© 2004-2009 NYSOPEP